1312579-08-0

Basic information

• Product Name: C₄₂H₃₅ClN₄O₄
• Synonyms: C₄₂H₃₅ClN₄O₄
• CAS NO: 1312579-08-0
• Molecular Weight: 695.217
• Mol File: 1312579-08-0.mol

Chemical Properties

• CAS DataBase Reference: C₄₂H₃₅ClN₄O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₂H₃₅ClN₄O₄(1312579-08-0)
• EPA Substance Registry System: C₄₂H₃₅ClN₄O₄(1312579-08-0)

Safety Data

• Hazardous Substances Data: 1312579-08-0(Hazardous Substances Data)

Upstream product

• 1312579-02-4 C₁₉H₁₉N₃O₅ 
• 1312579-06-8 C₃₀H₂₆ClN₃O₄ 
• 1357089-52-1 C₃₂H₃₂ClN₃O₅ 
• 1357089-50-9 C₃₂H₃₂ClN₃O₆ 
• 1357089-48-5 C₃₂H₃₀ClN₃O₈ 
• 60336-03-0 5-(4-chlorophenyl)furan-2-carboxylic acid ethyl ester 
• 41019-45-8 5-(4-chlorophenyl)-2-furoic acid 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 1312579-07-9 C₃₇H₃₁BrClN₃O₄ 
• 1692-25-7 3-pyridylboronic acid 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 

Downstream Products

• 1312578-79-2 C₃₄H₂₉ClN₄O₂ 

Relevant articles and documents

Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors

Conformation restriction of linear N-alkylanilide MK2 inhibitors to their E-conformer was developed. This strategy enabled rapid advance in identifying a series of potent non-ATP competitive inhibitors that exhibited cell based activity in anti-TNFα assay.

FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.